Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer.
Deng WangGenyu DuXinyu ChenJinming WangKaiyuan LiuHuifang ZhaoChaping ChengYuman HeNa JingPenghui XuWei BaoXialian XiYingchao ZhangNan WangYiyun LiuYujiao SunKai ZhangPengcheng ZhangWei-Qiang GaoHelen He ZhuPublished in: Cell death and differentiation (2024)
Cell plasticity has been found to play a critical role in tumor progression and therapy resistance. However, our understanding of the characteristics and markers of plastic cellular states during cancer cell lineage transition remains limited. In this study, multi-omics analyses show that prostate cancer cells undergo an intermediate state marked by Zeb1 expression with epithelial-mesenchymal transition (EMT), stemness, and neuroendocrine features during the development of neuroendocrine prostate cancer (NEPC). Organoid-formation assays and in vivo lineage tracing experiments demonstrate that Zeb1 + epithelioid cells are putative cells of origin for NEPC. Mechanistically, Zeb1 transcriptionally regulates the expression of several key glycolytic enzymes, thereby predisposing tumor cells to utilize glycolysis for energy metabolism. During this process, lactate accumulation-mediated histone lactylation enhances chromatin accessibility and cellular plasticity including induction of neuro-gene expression, which promotes NEPC development. Collectively, Zeb1-driven metabolic rewiring enables the epigenetic reprogramming of prostate cancer cells to license the adeno-to-neuroendocrine lineage transition.
Keyphrases
- epithelial mesenchymal transition
- gene expression
- prostate cancer
- transforming growth factor
- poor prognosis
- signaling pathway
- induced apoptosis
- dna methylation
- long non coding rna
- single cell
- cell cycle arrest
- dna damage
- transcription factor
- radical prostatectomy
- oxidative stress
- mesenchymal stem cells
- pi k akt
- stem cells
- gene therapy
- smoking cessation